Background. We examined whether a high-dose inactivated influenza vaccine was more efficacious in preventing hospitalizations than a standard-dose vaccine in the Veterans Health Administration (VHA) senior population.
Seasonal influenza epidemics have a substantial public health and economic burden in the United States. On average, more than 200 000 people are hospitalized and upwards of 49 000 people are estimated to die each year from respiratory and circulatory complications associated with seasonal influenza virus infections [1] [2] [3] [4] [5] [6] [7] . Medical complications leading to hospitalizations and deaths are greatest among persons aged 65 years and older (hereinafter referred to as seniors) [4] . The heightened susceptibility to complications is largely due to the progressive age-related weakening of the immune system known as immunosenescence that also renders seniors less responsive to vaccines. In 2009, the US Food and Drug Administration licensed an injectable high-dose inactivated trivalent influenza vaccine (Fluzone High-Dose, Sanofi Pasteur, PA), hereinafter referred to as the high-dose vaccine (HD). High-dose vaccine contains 4 times more influenza hemagglutinin antigen than standard-dose influenza (SD) vaccines (60 μg vs 15 μg per strain); designed to improve immune response and therefore protection in seniors.
Analyses comparing the HD and SD vaccines in preventing influenza-related hospitalizations have generated inconsistent results. A randomized clinical trial (RCT) comparing HD and SD in seniors during the 2011-2012 and 2012-2013 respiratory seasons found a relative vaccine effectiveness (rVE) of 24.2% (95% confidence interval [CI], 9.7%-36.5%) against laboratory-confirmed influenza [8] . In addition, the rate of all-cause hospitalization was calculated to be 6.9% (95% CI, 0.5%-12.8%) lower in the HD group than in the SD group; the rate of serious pneumonia was 39.8% (95% CI, 19.3%-55.1%) lower in the HD group; and the rate of serious cardiorespiratory medical events possibly related to influenza was 17.7% (95% CI, 6.6%-27.4%) lower in the HD group [9] . A subsequent observational study further supported the benefit of HD versus SD vaccination when comparing 2 outcomes in US Medicare beneficiaries during the 2012-2013 respiratory season [10] . The authors found a relative benefit for HD over SD against rapid response influenza test followed by oseltamivir treatment (22%; 95% CI, 15%-29%) and against influenza attributed hospitalization or emergency department visits (22%; 95% CI, 16%-27%). In contrast, a study among community-dwelling senior US Veterans during the 2010-2011 respiratory season found HD no more effective than SD in preventing influenza-attributed hospitalizations, with a calculated relative efficacy of only 2% (95% CI, −40% to 32%) [11] .
Previous observational studies have differed by study design details such as inclusion/exclusion criteria, timeframe, and outcomes, warranting additional examination of the effectiveness of the HD as necessary guidance for clinical practice and public policy, especially for Veterans.
In observational studies of treatment effectiveness, confounding by indication is well recognized but challenging to rectify when confounders are difficult to quantify due to a lack of clear definition and verifiable measures. One such confounder, in this case, is frailty-a geriatric condition characterized by an increased risk of catastrophic declines in health and function among older adults [12, 13] . It is possible that 2 individuals of the same age, sex, and with the same number of documented comorbid conditions could have considerable differences in their frailty that would be obvious to an examining physician but elusive to a researcher considering only claims and electronic medical records. With these considerations, we conducted a retrospective cohort study to estimate rVE of HD versus SD influenza vaccine in senior US Veterans, using a methodology particularly designed to adjust for confounding by indication induced by unmeasured differences in frailty.
METHODS

Design and Data Sources
We conducted a retrospective cohort study among senior Veterans Health Administration (VHA) patients during the 2015-2016 influenza season. We studied 3 categories of outcomes: (1) influenza-or pneumonia-associated with a hospital or outpatient visit, (2) all-cause hospital or outpatient visit, and (3) any medical encounter with a positive influenza test.
The VHA is the single largest integrated healthcare system in the United States and provides care to military veterans at 144 medical centers, 1203 community-based outpatient clinics, and 300 Veteran Centers. As of 2015, there were over 6 million patients with healthcare service records in the VHA. The VHA has an integrated and unified electronic medical record (EMR) system that stores information about all inpatient, emergency, and outpatient visits as well as laboratory tests and medication prescriptions. Each patient is assigned a unique identification number that allows for longitudinal follow-up.
Study Population and Influenza Vaccination
The study population included all VHA patients 65 years and older with at least 1 inpatient or outpatient encounter in prior respiratory season of 2014-2015. This restriction improves the probability of capturing comorbidities and reduces the chance that participants were incidental VHA users. Influenza vaccination was identified using Current Procedural Terminology (CPT) codes (SD vaccine CPT codes: 90655-90659 and Q2034-Q2039; HD vaccine CPT code: 90662). We applied a number of exclusion criteria to reduce the chances of misclassification and to ensure valid comparison. First, Veterans who self-reported vaccination were excluded, because HD and SD vaccines are similar in presentation and administration making them hard to distinguish by recipients. Second, we excluded all Veterans who had received more than 1 influenza vaccine in the respiratory season of inquiry (2015) (2016) . Third, we excluded patients who had received an influenza vaccine in any region other than their typical region of care (ie, "snowbirds" or patients with dual residencies) to simplify matching. Fourth, we excluded facilities with HD-vaccination rates lower than 5% (in other words, at least 5% of all patients vaccinated at the facility received a HD) to ensure adequate supply of HD at that facility. Finally, recipients of either influenza vaccination during the 6 months before the start of baseline period (began at the end of the respiratory season in week 27 [beginning of July] of 2015 and ran until the vaccination date) were excluded so as to minimize any potential impacts from previous season vaccination. The study received institutional review board approval from the Veteran's Institutional Review Board of Northern New England at the White River Junction VA Medical Center and the Geisel School of Medicine at Dartmouth.
Baseline and Observation Period
The baseline period began at the end of the respiratory season in week 27 (beginning of July) of 2015 and ran until the vaccination date [3, 5, 6] . The observation period spanned from 2 weeks after vaccination to the end of the respiratory season in week 26 (end of June) of 2016 ( Figure 1 ).
Baseline Characteristics
In addition to demographic characteristics, subjects were classified by the presence of specific health conditions during the period from the beginning of the previous respiratory season to the date of vaccination. Medical conditions considered in this study included the following: chronic cardiac, pulmonary, renal, metabolic, liver, and neurological diseases; diabetes mellitus; hemoglobinopathies; immunosuppressive conditions; and malignancy. These were identified based on primary diagnosis codes (International Classification of Diseases [ICD]-9/10) from outpatient visits and hospital admissions.
We selected the Care Assessment Need (CAN) score as a proxy measure for frailty. The CAN score, much like the commonly used Charlson and Elixhauser comorbidity scores, is used to predict hospitalization within 1 year; however, CAN was developed specifically for VHA population, and it was validated using 4.6 million VHA patients. In addition to incorporating the medical conditions essential to the Charlson and Elixhauser comorbidity scores, CAN includes predictors such as sociodemographic characteristics, prior year healthcare utilization, medications, and laboratory tests (some of which are unique to Veterans Administration [VA] EMR data) [14] . We used the maximum CAN score in the 4 weeks before vaccination.
Outcomes
The primary outcome of the study was any hospitalization in which the patient record indicated either pneumonia or influenza (ICD-9: 480-488) as a principal or secondary diagnosis. Four additional outcomes were explored: (1) outpatient visits (defined as a visit to a primary care physician, emergency department, or urgent care provider) where the patient record indicated pneumonia or influenza as a principal or secondary diagnosis; (2) patient record documenting laboratory-confirmed influenza; (3) all-cause outpatient visits; and (4) all-cause hospitalizations.
Statistical Analysis
Outcome rates were calculated for both HD and SD cohorts during each period (baseline and observation). We calculated a person-time denominator by summing the number of weeks that patients were enrolled for each period. The numerator was the total number of outcomes (including multiple outcomes for a single patient) by period.
Our primary analysis adjusted for confounding by matching HD recipients to SD recipients on factors described above under Baseline Characteristics. After matching (described below), we adjusted for residual confounding using the prior event rate ratio (PERR) approach [15] [16] [17] [18] [19] . This method, similar to the difference-in-differences method used in econometrics, involves the definition of 2 periods, one before the interventions (eg, HD and SD) and another after [20] . For each intervention group, the rates of an outcome can be calculated and compared before and after the intervention. To assess the impact of the intervention, the relative rate of the postintervention period was divided by the relative rate of the preintervention period.
To apply the PERR method, we first computed the incidence rate ratio (RR) for each study outcome in the observation period (RR o ) and then again in the baseline period (RR b ). The RR is the rate of the outcome in HD recipients divided by the rate of the outcome in SD recipients in any given period. Next, we computed the PERR per the following formula:
and, finally, the rVE of HD to SD as follows:
Matching
For every HD vaccine recipient at one of the 1347 VA facilities, we selected between 1 and 4 other patient(s) at the same facility who received a SD vaccine within 1 week from the HD vaccination date, either before or after. This process addressed temporal and geographic factors possibly associated with access to HD (eg, supply) and influenza disease exposure (ie, viral activities). To adjust for confounding by indication, we also matched patients on the presence of 2 or more pre-existing medical comorbidities. We assessed the effectiveness of matching in balancing patient characteristics by comparing the standardized differences in means for baseline characteristics between HD and SD vaccination groups. Both unmatched and matched populations were analyzed with the PERR method and results were shown side by side.
Sensitivity Analysis
A sensitivity analysis using generalized estimating equations (GEE) was performed [21] . The GEE was selected to account for clustering at both the patient and facility levels and to adjust explicitly for individual characteristics and facility-level factors such as HD adoption rates. The interaction term between intervention (HD vs SD) and period (baseline and observation) was used to estimate the rVE. To be more representative of the VHA patient population, we applied this sensitivity analysis to an unmatched cohort that included subjects with self-reported vaccinations and those sites with HD adoption rates lower than 5%. Relaxing the exclusion criteria quadrupled our cohort size from one quarter of a million in our main analysis to one million in the sensitivity analysis. An autoregressive of first-order correlation structure was applied. Relative risk estimates were obtained from the GEE model, and CIs were calculated using a robust covariance estimator for the estimated effects.
RESULTS
We identified 1.3 million Veterans with documented CPTcoded influenza vaccinations during the 2015-2016 influenza season. After applying exclusion criteria, the study population before matching consisted of 104 965 and 125 776 Veterans in the SD and HD cohorts, respectively ( Figure 2 ). The HD cohort was slightly older than the SD cohort, respectively, averaging 73.9 and 72.7 years of age (Table 1) , whereas sex and race were equally distributed between the cohorts. The SD recipients were vaccinated in facilities with an average HD proportion of 27%, whereas vaccinations of HD recipients occurred in facilities with an average HD proportion of 79%. Because facilities with high and low HD proportions are not evenly distributed across the country, we found substantial differences in the prevalence of HD versus SD by region. In VA Region 9 (Arizona, California, Guam, Hawaii, Nevada), for instance, the majority of Veterans received the HD vaccine (24 495 HD versus 6860 SD recipients); in Region 4 (southeastern United States), the majority received the SD (3696 HD versus 11 916 SD recipients). However, this imbalance was ameliorated through matching. During the baseline period, we observed a higher rate of hospitalization where influenza or pneumonia was present in Table 2 ). In contrast, during the observation period, rates of hospitalization for influenza or pneumonia were nearly identical between the 2 groups, resulting in a RR of 0.99 (95% CI, 0.95-1.03). The PERR-adjusted rVE estimate of HD against influenza-or pneumonia-associated hospitalization in the unmatched cohort was 23% (95% CI, 9%-35%).
After matching, the study population comprised 49 091 and 24 682 Veterans for the SD and HD cohorts, respectively, which, as expected, were more similar to one another than were the unmatched cohorts for the majority of baseline characteristics ( Table 1) . We subsequently found a marginally higher rVE estimate against influenza-or pneumonia-associated hospitalization of 25% (95% CI, 2%-43%; Table 2 ).
For our secondary outcomes, the PERR-adjusted rVE estimate of HD against influenza-or pneumonia-associated outpatient visits in the unmatched cohort was 7% (95% CI, −7% to 18%); matching resulted in an adjusted estimate of 14% (95% CI, −8% to 32%). In the unmatched cohort, the PERR-adjusted rVE for all-cause hospitalizations and for all-cause outpatient visits was 0% (95% CI, −5% to 5%) and 2% (95% CI, 1%-4%), respectively. The PERR-adjusted rVEs for all-cause outcomes in the matched cohort were slightly higher at 7% (95% CI, −2% to 14%) against hospitalizations and 5% (95% CI, 2%-8%) against outpatient visits.
During the observation period, the influenza diagnostic test rate in SD recipients was 3.92 per 10 000 person-weeks (120 were positive and 1221 negative) and 3.54 per 10 000 person-weeks in the HD recipients (99 positive and 1322 negative; Table 3 ). Laboratory-confirmed influenza rates were 0.35 versus 0.24 per 10 000 person-weeks in the SD and HD cohort, respectively, resulting in an rVE of 30% (95% CI, 8%-47%). Matching resulted in a higher test rate in HD than in SD recipients (4.39 vs 3.95 per 100 000 person-weeks, respectively) and in an rVE of 38% (95% CI, −5% to 65%). Laboratory-confirmed influenza rate was nil in the baseline period of the study, and as such we did not apply PERR adjustments to the rVE estimates against this outcome.
Sensitivity Analysis Results
Using the GEE method, we found an overall rVE of 29% (95% CI, 14%-41%) against influenza-or pneumonia-associated hospitalization. For age groups 65 to 74, 75 to 84, and 85 or older, the respective rVEs were as follows: 23% (95% CI, 10%-33%), 26% (95% CI, 8%-40%), and 30% (95% CI, 15%-42%) against influenza-or pneumonia-associated hospitalization.
DISCUSSION
Our main result, a matched and PERR-adjusted HD vaccine rVE of 25% (95% CI, 2%-43%) against influenza-or pneumonia-associated hospitalization, is consistent with the rVE of 40% (95% CI, 20%-45%) against pneumonia admission found from the RCT reported by DiazGranados et al [8] . In addition, we note consistency between our results and those observed when comparing rVE estimates against both our broadest outcome category and our most specific outcome: for all-cause admission, our estimate of 7% (95% CI, −2% to 14%) is consistent with the RCT rVE of 8% (95% CI, 2%-12%), and our rVE of 38% (95% CI, −5% to 65%) against laboratory-confirmed influenza is consistent with the RCT estimate of 24.2% (95% CI, 9.7%-36.5%) against laboratory-confirmed influenza-like illness. Our rVE against laboratory-confirmed influenza also aligns with the result reported by Izurieta et al [10] for 2 comparable outcomes: rapid response influenza test followed by oseltamivir treatment (22%; 95% CI, 15%-29%) and influenza-attributed hospitalizations or emergency department visits (22%; 95% CI, 16%-27%). Although they were not the focus of Shay et al's [22] evaluation of the comparative effectiveness of HD in preventing postinfluenza deaths during the 2012-2013 and 2013-2014 seasons, rVE estimates for hospitalized influenza and influenza-related illness were reported to be 18.8% (95% CI, 14.4%-23%) and 14.2% (95% CI, 8.5%-19.4%), respectively, which are in accord with our findings. Reporting from the first cluster-randomized, prospective study to investigate the relative effectiveness of HD vaccine in an elderly nursing home population, Gravenstein et al [23] found HD vaccine to be more effective than SD vaccine in reducing both respiratory illness (12.7%; 95% CI, 1.8%-22.4%) and all-cause hospital admissions (6.7%; 95% CI, 1.5%-11.6%) in the 2013-2014 season, also consistent with our findings. Richardson et al [11] studied a cohort of senior Veterans, similar to ours. In contrast, for influenza-related and pneumonia-attributed hospitalizations, they reported a relative efficacy of only 2% (95% CI, −40% to 32%). Several methodological differences may explain our divergent findings. First and foremost is our use of the PERR method: we specifically selected this instrument to adjust for confounding by indication induced by unmeasured variables, a factor Richardson et al [11] did not fully address by including influenza or pneumonia hospitalization before the influenza season as an adjustment variable in their multivariate Poisson regression model. Furthermore, Richardson et al's [11] use of stratification by propensity score quintile to adjust for measured confounders is problematic given the low frequency of HD vaccine usage in the population across the study period [24] . Stratifying in this way may have little impact on adjusting for measured confounders when the exposure to study treatment is rare and the quintiles are based on the entire cohort rather than the exposed subcohort, as demonstrated recently by Desai et al [25] . Moreover, Richardson et al [11] did not address bias introduced due to temporal and geographic factors associated with both vaccine access and influenza exposure. Our analysis has several limitations. First, we could not apply PERR adjustment to our most specific outcome (laboratory-confirmed influenza) because the outcome was not observed in the baseline period. This lack of adjustment could result in an underestimate of rVE of HD for 2 reasons: (1) the US Centers for Disease Control and Prevention reported a close match between the circulating influenza strains and the strains included in the vaccine for the 2015-2016 season; and (2) DiazGranados et al [8] reported in their RCT an rVE of 51% against laboratory-confirmed influenza strains similar to vaccine strains [15] . Taken together, these facts imply that without a PERR adjustment to this highly specific outcome, an rVE of 38% is likely an underestimate. Because we were interested in the impact on the overall health service utilization (eg, allcause hospitalizations and all-cause outpatient visits) during the entire influenza season, we did not restrict our analyses to periods of peak influenza activities as some past studies have done. One consequence of using the broader period is bias towards the null arising from misclassification of study outcomes [26] . The differences among our estimates of rVE based on the more specific outcome, ie, laboratory-confirmed influenza, and our less specific outcomes such as all-cause outpatient visits, suggest such a bias.
Second, the matched PERR analysis is appealing because PERR is a straightforward adaptation of the difference-in-differences method and matching is effective in control for confounding. However, this primary analysis neglects both a potential clustering effect within facilities and correlations between repeated observations for the same patient. Thus, a sensitivity analysis using the GEE method was also performed. Nonetheless, because treatment allocation was not randomized in our study, the potential for confounding by indication and by unmeasured variables cannot be entirely eliminated. Third, VHA patients also use healthcare services outside the VHA, and our study captured and used data only from their VHA encounters. Because the observation period immediately followed the baseline period and we excluded "snowbirds, " it seems unlikely that many patients could have significantly changed their healthcare behavior, in terms of seeking care outside the VA, from one period to the next. In addition, the similarity between the matched SD and the HD recipients, as demonstrated in Table 2 , also suggested that a meaningful difference between the 2 groups in terms of seeking care outside the VA was unlikely. Consequently, it is plausible that the PERR method produces low-bias estimates because the missing data regarding healthcare outside the VHA is unlikely to be differential between periods or between groups. Finally, the generalizability of our findings should be interpreted in the context of our source population, which comprise patients treated at VHA facilities and, therefore, may have limited applicability to seniors in the US general population. Moreover, as demonstrated by Shay et al [22] , different results (eg, strength of association) might be observed in years when the relatedness of vaccine and circulating strains are materially different. Of the 5 seasons that have been studied (2010-2011 to 2013-2014 , and ours, 2015-2016), HD's higher relative effectiveness was observed in all but onethe 2010-2011 season.
CONCLUSIONS
In protecting senior VHA patients against influenza-or pneumonia-associated hospitalization, HD vaccine was more effective than SD vaccine. This relative effectiveness was demonstrated using EMRs that included hospitalizations and laboratory results for a vulnerable population receiving healthcare in a real-world setting. Because our study was conducted in a different influenza season than those studies and trials mentioned above, our results may have been impacted by the severity of influenza seasons, virus type and subtype, and the match between the vaccine and circulating influenza strains. We plan to investigate the effectiveness of HD vaccine in a more timely fashion (eg, within 3 months from the end of a season) as we automate our data extraction processes and standardize our methodology.
Notes
